Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Horowitz, Mary M  [Clear All Filters]
2013
Saber W, Cutler CS, Nakamura R, Zhang M-J, Atallah E, J Rizzo D, Maziarz RT, Cortes J, Kalaycio ME, Horowitz MM. Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS). Blood. 2013.
Koreth J, Pidala J, Perez WS, H Deeg J, Garcia-Manero G, Malcovati L, Cazzola M, Park S, Itzykson R, Ades L, et al. Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis. J Clin Oncol. 2013.
2014
Arora M, Hemmer MT, Ahn KWoo, Klein JP, Cutler CS, Urbano-Ispizua A, Couriel DR, Alousi AM, Gale RPeter, Inamoto Y, et al. CIBMTR Chronic GVHD Risk Score Predicts Mortality in an Independent Validation Cohort. Biol Blood Marrow Transplant. 2014.
Wagner JE, Eapen M, Carter S, Wang Y, Schultz KR, Wall DA, Bunin N, Delaney C, Haut P, Margolis D, et al. One-Unit versus Two-Unit Cord-Blood Transplantation for Hematologic Cancers. N Engl J Med. 2014;371(18):1685-1694.
Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME, Maziarz RT, Antin JH, Soiffer RJ, Weisdorf DJ, et al. Validation and refinement of the disease risk index for allogeneic stem cell transplantation: a study from the CIBMTR. Blood. 2014.
2015
Khera N, Majhail NS, Brazauskas R, Wang Z, He N, Aljurf MD, Akpek G, Atsuta Y, Beattie S, Bredeson CN, et al. Comparison of Characteristics and Outcomes of Trial Participants and Non-participants: Example of Blood and Marrow Transplant Clinical Trials Network (BMT-CTN) 0201 Trial. Biol Blood Marrow Transplant. 2015.
Young J-AH, Logan BR, Wu J, Wingard JR, Weisdorf DJ, Mudrick C, Knust K, Horowitz MM, Confer DL, Dubberke ER, et al. Infections following Transplantation of Bone Marrow or Peripheral-Blood Stem Cells from Unrelated Donors. Biol Blood Marrow Transplant. 2015.
2018
Pulsipher MA, Logan BR, Chitphakdithai P, Kiefer DM, Riches ML, J Rizzo D, Anderlini P, Leitman SF, Varni JW, Kobusingye H, et al. The Effect of Aging and Pre-Donation Comorbidities on the Related PBSC Donor Experience: A Report from the Related Donor Safety Study (RDSafe). Biol Blood Marrow Transplant. 2018.
Pulsipher MA, Logan BR, Kiefer DM, Chitphakdithai P, Riches ML, J Rizzo D, Anderlini P, Leitman SF, Varni JW, Kobusingye H, et al. Higher risks of toxicity and incomplete recovery in 13-17 year old females after marrow donation: RDSafe peds results. Biol Blood Marrow Transplant. 2018.
2019
Atallah E, Logan B, Chen M, Cutler C, Deeg J, Jacoby M, Champlin R, Nishihori T, Confer D, Gajewski J, et al. Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome: The Medicare Coverage With Evidence Development Study. JAMA Oncol. 2019.
2020
Koenig K, Mims A, Levis MJ, Horowitz MM. The Changing Landscape of Treatment in Acute Myeloid Leukemia. Am Soc Clin Oncol Educ Book. 2020;40:1-12.
Hamadani M, Zhang M-J, Tang X-Y, Fei M, Brunstein C, Chhabra S, D'Souza A, Milano F, Phelan R, Saber W, et al. Graft cryopreservation does not impact overall survival allogeneic hematopoietic cell transplantation using post-transplant cyclophosphamide for GVHD prophylaxis. Biol Blood Marrow Transplant. 2020.
Switzer GE, Bruce JG, Kiefer DM, Kobusingye H, Abebe KZ, Drexler R, Besser RAM, Confer DL, Horowitz MM, King RJ, et al. Health-Related Quality-of-Life Comparison of Adult Related and Unrelated HSC Donors: An RDSafe Study. Biol Blood Marrow Transplant. 2020.
Algwaiz G, Aljurf M, Koh M, Horowitz MM, Ljungman P, Weisdorf D, Saber W, Kodera Y, Szer J, Jawdat D, et al. Real-world issues and potential solutions in HCT during the COVID-19 pandemic: Perspectives from the WBMT and the CIBMTR's Health Services and International Studies Committee. Biol Blood Marrow Transplant. 2020.
2023
Cho C, Devlin S, Maloy M, Horowitz MM, Logan B, J Rizzo D, Giralt SA, Perales M-A. Application of the CIBMTR One Year Survival Outcomes Calculator as a tool for retrospective analysis. Bone Marrow Transplant. 2023.
Jurdi NEl, Martens MJ, Brunstein CG, O'Donnell P, Lee SJ, D'Souza A, Logan B, Hong S, Singh AK, Sandhu K, et al. Heath-related Quality of Life in Double Umbilical Cord Blood vs. Haploidentical Marrow Transplantation: a QOL Analysis Report of BMT CTN 1101. Transplant Cell Ther. 2023.
Bolaños-Meade J, Hamadani M, Wu J, Malki MMAl, Martens MJ, Runaas L, Elmariah H, Rezvani AR, Gooptu M, Larkin KT, et al. Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis. N Engl J Med. 2023;388(25):2338-2348.
2024
Atsuta Y, Baldomero H, Neumann D, Sureda A, DeVos JD, Iida M, Karduss A, Purtill D, Elhaddad AM, Bazuaye NG, et al. Continuous and differential improvement in worldwide access to hematopoietic cell transplantation: activity has doubled in a decade with a notable increase in unrelated and non-identical related donors. Haematologica. 2024.
Pasquini MC, Wallace PK, Logan B, Kaur M, Tario JD, Howard A, Zhang Y, Brunstein C, Efebera Y, Geller N, et al. Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival. J Clin Oncol. 2024:JCO2300934.